Rate My Professor marian burr

Her research specializes in cancer cell biology, epigenetics, and immune regulation, with a clinical emphasis on lung cancer and thoracic malignancies pathology. Burr employs genome-scale functional genetic screening to identify mechanisms of cancer immune evasion and strategies to overcome immunotherapy resistance. Notable publications include "Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes" (Nature Cell Biology, 2023); "Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses" (Cancer Cell, 2022); "An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer" (Cancer Cell, 2019, reprinted in Cancer Cell ‘Best of 2019’); "CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity" (Nature, 2017); and "MHC class I molecules are preferentially ubiquitinated on endoplasmic reticulum luminal residues during HRD1 ubiquitin E3 ligase-mediated dislocation" (PNAS, 2013). These high-impact contributions have influenced drug discovery programs targeting PD-L1 regulators and epigenetic inhibitors for enhanced anti-tumor immunity in solid and haematological cancers.